Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

Zeidner Joshua F.; Knaus Hanna; Zeidan Amer M.; Blackford Amanda; Montiel-Esparza Raul; Prince Gabrielle T.; Gondek Lukasz P.; Ghiaur Gabriel; Showel Margaret M.; DeZern Amy E.; Pratz Keith W.; Smith B. Douglas; Levis Mark J.; Foster Matthew C.; Coombs Catherine C.; Streicher Howard; Karp Judith E.; Luznik Leo; Gojo Ivana

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

【24h】

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

机译：在急性髓性白血病（AML）和高危髓细胞（HR-MDS）中，在诱导定时顺序治疗（TST）期间从早期淋巴细胞恢复开始的乳氨基醛醛的有效免疫调节

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Zeidner Joshua F.; Knaus Hanna; Zeidan Amer M.; Blackford Amanda; Montiel-Esparza Raul; Prince Gabrielle T.; Gondek Lukasz P.; Ghiaur Gabriel; Showel Margaret M.; DeZern Amy E.; Pratz Keith W.; Smith B. Douglas; Levis Mark J.; Foster Matthew C.; Coombs Catherine C.; Streicher Howard; Karp Judith E.; Luznik Leo; Gojo Ivana;
展开▼
作者单位

Univ N Carolina Lineberger Comprehens Canc Ctr Chapel Hill NC 27515 USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Yale Univ New Haven CT USA;

Johns Hopkins Univ Sch Med Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Univ N Carolina Lineberger Comprehens Canc Ctr Chapel Hill NC 27515 USA;

Univ N Carolina Lineberger Comprehens Canc Ctr Chapel Hill NC 27515 USA;

Natl Canc Inst Canc Therapy Evaluat Program Bethesda MD USA;

Johns Hopkins Univ Sch Med Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

Johns Hopkins Univ Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
专利

1. Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS) [J] . Zeidner Joshua F., Knaus Hanna, Zeidan Amer M., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在急性髓性白血病（AML）和高危髓细胞（HR-MDS）中，在诱导定时顺序治疗（TST）期间从早期淋巴细胞恢复开始的乳氨基醛醛的有效免疫调节
2. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. [J] . Heidel F, Cortes J, Rucker FG, Cancer: A Journal of the American Cancer Society . 2007,第5期

机译：使用低剂量Ara-C和伊马替尼对c-Kit阳性急性髓细胞性白血病（AML）和高危骨髓增生异常综合征（HR-MDS）的老年患者进行的多中心II期试验的结果。
3. High dose cytarabine and mitoxantrone: An effective induction regimen for high-risk Acute Myeloid Leukemia (AML) [J] . LarsonS.M., CampbellN.P., HuoD., Leukemia and lymphoma . 2012,第3期

机译：高剂量阿糖胞苷和米托蒽醌：一种有效的诱导方案，可治疗高危急性髓性白血病（AML）
4. K-Means Clustering on 3^rd order polynomial based normalization of Acute Myeloid Leukemia (AML) and Acute Lymphocyte Leukemia (ALL) [C] . Mehdi A.M., Sehgal M.S., Zayegh A., Electrical Engineering, 2009. ICEE '09 . 2009

机译：基于3 ^{rd 多项式的K均值聚类基于急性髓细胞白血病（AML）和急性淋巴细胞白血病（ALL）的归一化}
5. Homeobox gene HOXA7 and chemotherapy resistance in acute myeloid leukemia (AML). [D] . Asimolowo, Olaniyi Adewuyi. 2006

机译：同源盒基因HOXA7与急性髓细胞白血病（AML）的化疗耐药性。
6. Myeloid Neoplasia: Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells [O] . Christopher G. Kanakry, Allan D. Hess, Christopher D. Gocke, -1

机译：髓样瘤形成：急性粒细胞性白血病密集定时序贯化疗后早期淋巴细胞恢复：调节性T细胞的外周寡克隆扩增
7. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration : a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG) [O] . Witte T.J.M. de, Suciu S., Peetermans M., 1995

机译：持续时间超过6个月的MDS后预后不良的骨髓增生异常（MDS）和继发性急性髓性白血病（sAML）的强化化疗：欧洲癌症研究与治疗组织（EORTC-LCG）白血病合作小组的一项初步研究

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

著录项

相似文献

相关主题

期刊订阅